1. Home /
    2. Altai Protocol Library /
  2. New Protocol: Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone with Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Protocol: Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone with Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma

New Protocol: Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone with Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma
Study:
  • Multicenter, single-arm, phase II trial
  • Newly diagnosed multiple myeloma (N:123)
  • High-risk cytogenetic abnormalities: 0:56 1:46 2:24 patients
  • Daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) plus AHCT, and Dara-KRd consolidation
Efficacy:
  • MRD negativity: 80%
  • MRD < 10–6: 66%
  • 2-year-PFS: 87% (91%, 97%, and 58% for patients with 0, 1, and 2+ HRCA)
  • 2-year-OS: 94%
Safety:
  • Any AEs: 100%, fatigue:55%, bone pain:55%, rash:41%, neutropenia:41%, lymphopenia:28%
  • Grade ≥3 AEs neutropenia 35%, lymphopenia:22%, hypertension:10%

J Clin Oncol. 2022 Sep 1;40(25):2901-2912.

Costa LJ, Chhabra S, Medvedova E, et al. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.

https://doi.org/10.1200/jco.21.01935

Reviewed by Hasan Çağrı Yıldırım, MD on Sep 27, 2022

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More